AI Article Synopsis
- The study treated 116 advanced/recurrent ovarian cancer patients and 102 uterine cancer patients using hyperthermia and immunotherapy between 2005-2013, after standard therapies were ineffective or declined.
- 29 (25%) ovarian cancer patients showed clinical benefit, with a combination of therapies achieving a 47.5% effective rate, while uterine cancer patients had a lower benefit rate of 12.7%.
- The effectiveness varied by cancer type, with cervical cancer, endometrial cancer, and uterine sarcoma having clinical benefit rates of 7.9%, 22.5%, and 12.5%, respectively, highlighting the potential of combined treatments.
Article Abstract
We treated 116 advanced or recurrent ovarian cancer and 102 uterine cancer patients with hyperthermia and/or immunotherapy(2005/7-2013/11). Of these, 63, 31, and 8 patients had cervical cancer, endometrial cancer, and uterine sarcoma, respectively. Standard therapy showed no effect or was refused by these patients. Twenty-nine(25.0%)ovarian cancer patients experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months). The effective rate of a combination of therapies including activated lymphocyte therapy, dendritic cell therapy, and hyperthermia was 47.5%. Thirteen(12.7%)uterine cancer patients experienced a clinical benefit. The effective rates for cervical cancer, endometrial cancer, and uterine sarcoma were 7.9%, 22.5%, and 12.5%, respectively. Both hyperthermia and immunotherapy were administered to successfully treat these patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!